Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that the Company’s CEO, James McIlroy, was awarded the title of ‘Young Pioneer of the Year’ at the inaugural Herald Scotland business awards.
The event, held at Glasgow Science Centre, recognised and rewarded innovation and sustainability at an international level, across all business sectors. The awards attracted entries from across the UK, from Aberdeen to London, as well as from the European mainland. It celebrated cross-sectoral innovators pioneering new ideas and products, particularly those helping to deliver a sustainable future and advance the United Nations Sustainable Development Goals.
Roy Gardner, executive director at City of Glasgow College, said: “Our congratulations go to a well-deserved winner whose ground-breaking project is helping to address and bridge the gender gap in STEM.”
For further information, please see the official article on the Herald website.
EnteroBiotix is a patient-centred biotechnology company developing novel medicinal products for use in infections or diseases associated with imbalances of bacteria in the human gut. The Company has established, staffed and integrated an ISO-accredited controlled donation facility and a fully equipped state-of-the-art manufacturing facility to manage collection, processing and formulation of medicinal products derived from healthy human donations. Headquartered in Aberdeen, EnteroBiotix has raised £700,000 in equity investment and non-dilutive funding with a dedicated core team of seven supported an Independent Scientific and Medical Advisory Board.
Aberdeen, Scotland –EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that it has raised £500,000 in an oversubscribed seed round of investment. The financing was led by Equity Gap and supported by the Scottish Investment Bank, the investment arm of Scottish Enterprise.
EnteroBiotix is developing orally-delivered encapsulated microbial therapeutics for use in a medical treatment called Faecal Microbiota Transplantation (also known as FMT or a stool transplant). The investment will be used to further develop the company’s product pipeline and grow its manufacturing and research team. The seed round includes £100,000 in non-dilutive funding from a SMART:Scotland feasibility grant to allow the company to develop entirely anaerobic (oxygen free) GMP-compliant collection and processing capabilities.
“This investment and grant funding will be pivotal in furthering the objectives of EnteroBiotix as we develop the first orally available products for FMT in Europe. We are excited to work with Equity Gap and Scottish Enterprise as we build EnteroBiotix into a dominant player this fast-moving field of science and medicine” says James McIlroy, a final year medical student at the University of Aberdeen and CEO at EnteroBiotix.
Fraser Lusty, Investor Director at Equity Gap, said: “We are delighted to provide the early equity to back James and the team at EnteroBiotix. He has impressed greatly with his vision, ambition and desire to create a business that will provide a much-needed solution for disease prevention and treatment. He has secured strong clinical and commercial collaborations, and the funding will be used to develop these to ensure the company meets its near-term objectives.”
Kerry Sharp, Head of the Scottish Investment Bank, said: “Scottish Enterprise has supported the company from an early stage in its development through the High Growth Ventures Unit and a SMART grant. We have chosen to continue to work with the company by supporting this seed round to help EnteroBiotix develops its exciting technology.”
By 2025, the human microbiome market is anticipated to be worth over $2.2 billion.
EnteroBiotix is set to make a first sale in early 2018 and will develop a significant amount of clinical experience from its market entry product offering. From there, the Company will leverage data from successful treatments to facilitate the development of rationally designed microbial therapeutics and to progress its assets through clinical trials. In addition, the Company is establishing a platform that will allow patients to bank their own bacteria before medical treatments that disturb the balances of bacteria in the gut, such as chemotherapy and long courses of antibiotics.
EnteroBiotix is an award-winning, patient-centered biotechnology company focused on using the body’s own microorganisms to prevent and treat debilitating infections and diseases. The Company’s lead product candidate is an orally administered microbial therapy for use in a medical treatment called Faecal Microbiota Transplantation (FMT). EnteroBiotix is using its manufacturing platform to develop allogenic (from a donor) and autologous (using a person’s own bacteria) orally delivered therapies, using standardised, quality controlled and quantifiable processes. EnteroBiotix recently came first place in the 2017 Oxford Biostars biotechnology competition, and the company has established several high-profile collaborations with commercial and academic partners.
For further information, please contact:
James McIlroy, CEO